#replicons

(YOUR STUFF IS REALLY COOL BY THE WAY!!!)

❝ but becoming stronger isn't a bad thing. ❞

Attack of the Replicons

The Biopharmaceutical Complex's self-amplifying mRNA assault has already begun.

NICOLAS HULSCHER, MPH

NOV 07, 2024

By Nicolas Hulscher, MPH

The Biopharmaceutical Complex is preparing for the large-scale deployment of replicon (self-amplifying) mRNA injections. There are currently at least 33 candidatesin development.

These products behave like a synthetic virus. The replicon mRNA is designed to encode not only the target antigen but also viral replicase, enabling the mRNA to replicate itself within the target cells. This replication machinery allows for an unknown period of toxic antigen production. Concerningly, none of the clinical trials have addressed the major concern of product shedding.

The Coalition for Epidemic Preparedness Innovations (CEPI) and the Biomedical Advanced Research and Development Authority (BARDA) are the primary funders behind this technology to combat ‘Disease X’. This is an extremely high risk ‘vaccine’ platform that should be avoided at all costs. Cellular installation of synthetic replicons requires decades of intense safety testing.

The very first replicon injection for human use received emergency use authorization (EUA) from The Office of the Drugs Controller General of India (DCGI) back in June 2022: Gennova Biopharmaceuticals’ GEMCOVAC-19. This was followed by reckless EUA approval in June 2023 for GEMCOVAC-OM, a replicon booster shot that targets the Omicron strain. 

In November 2023, Japan's Ministry of Health, Labor and Welfare (MHLW) fully approved CSL and Arcturus Therapeutics' replicon shot: KOSTAIVE ARCT-154. Dismissing all concerns, Japan’s MHLW approved the updated booster shot in September 2024 to target the JN.1 lineage of Omicron subvariants.

In the clinical trials for ARCT-154, 5 deaths occurred among the injected in study phase 3b. Injected participants experienced a 90% adverse event rate (74.5% systemic - 15.2% required medical attention) after the first dose in study phases 1, 2, and 3a combined. Many of the authors are full time employees of Arcturus Therapeutics, meaning their conclusions are likely biased. 

Meanwhile, the USDA quietly approved an experimental self-amplifying RNA injection for dogs developed by Merck in June 2024: Nobivac NXT Canine Flu H3N2. It appears that Merck is attempting to camouflage the fact that this product is self-amplifying. The primary product description only indicates that it uses “revolutionary RNA particle technology.” However, the novel platform works by RNA particles targeting dendritic cells, where they self-replicate and result in sustained antigen production. 

The possibility of product shedding from dogs to humans or other animals was never tested. This injection is currently widely available for online purchase and canine administration. While the Biopharmaceutical Complex struggles to get self-amplifying mRNA injections approved for humans, they seem to have no problem targeting our pets.

Deployment of this experimental platform has continued in September 2024 to target cats: Nobivac NXT FeLV. Nowhere in the product brochure does it mention the RNA self-amplification mechanism of action. They hope that unsuspecting vets won't think twice about accepting the 'new and improved' product. The so-called 'safety' data for this product is as follows: 

“Demonstrated safety under field conditions" from "Data on file. Merck Animal Health." 

❝ each fish in the ocean swims in its own direction. ❞